Ablexis Appoints Sean Stevens, Ph.D., as Vice President, Research

Published: Nov 18, 2010

SAN FRANCISCO--(BUSINESS WIRE)--Ablexis, LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for antibody drug discovery, announced today the appointment of Sean Stevens, Ph.D., as vice president, research. Reporting to Larry L. Green, Ph.D., chief executive officer of Ablexis, Dr. Stevens will lead the development and assist in the ongoing commercialization of the AlivaMab Mouse platform.

Back to news